Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 10/20 | 0.42 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SLC43A1 | O75387 | 1/20 | 0.39 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.38 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26823569 | 1.00 | GAA (0.43) | GAAABCB1PTGES2TSHRSLC43A1 | |
| SCHEMBL26823559 | 1.00 | GAA (0.43) | GAAABCB1PTGES2TSHRSLC43A1 | |
| SCHEMBL26830534 | 0.84 | ABCB1 (0.43) | GAAABCB1PTGES2TSHRSLC43A1 | |
| SCHEMBL26824463 | 0.84 | ABCB1 (0.43) | GAAABCB1PTGES2TSHRSLC43A1 | |
| SCHEMBL14929138 | 0.80 | GAA (0.44) | GAAABCB1PTGES2TSHRLGALS9 | |
| SCHEMBL6673470 | 0.76 | LGALS9 (0.44) | GAAABCB1TSHRLGALS9LGALS1 | |
| SCHEMBL6673468 | 0.76 | LGALS9 (0.44) | GAAABCB1TSHRLGALS9LGALS1 | |
| SCHEMBL38660870 | 0.75 | GAA (0.53) | GAAABCB1TSHRMEN1KMT2A | |
| SCHEMBL14293976 | 0.75 | LGALS9 (0.43) | GAAABCB1TSHRLGALS9LGALS1 | |
| SCHEMBL13714182 | 0.75 | LGALS9 (0.43) | GAAABCB1TSHRLGALS9LGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | REATA PHARMACEUTICALS, INC (US) | 2023-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | HSPA2, HSP90AB2P, HSF1 | GAA 315/4885ABCB1 364/4885PTGES2 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.